HealthDay on MSN16h
Talazoparib + Enzalutamide Tied to Improved Overall Survival in Metastatic Prostate CancerFor patients with metastatic castration-resistant prostate cancer (mCRPC) unselected for homologous recombination repair (HRR ...
NEW YORK, NY / ACCESS Newswire / February 19, 2025 / If you suffered a loss on your ESSA Pharma Inc. (NASDAQ:EPIX) investment and want to learn ...
Shareholders who purchased shares of EPIX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required ...
Talazoparib plus enzalutamide boosts overall survival in metastatic castration-resistant prostate cancer, with HRR-deficient ...
If you purchased or acquired securities in ESSA Pharma between December 12, 2023 and October 31, 2024 and would like to ...
Phase 2 of the M-E Combination Study compared this recommended combination dose with a 160 mg QD enzalutamide monotherapy—the standard of care for the intended patient population. The primary ...
which showed a much higher rate of PSA90 response in patients treated with enzalutamide monotherapy . . . than were expected based upon historical data” and “no clear efficacy benefit seen ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback